lamdis

How to appeal a Rybelsus denial

Reviewed · 17 sources

The short answer

Rybelsus is a type 2 diabetes drug, and plans usually deny it for one of three reasons: the request did not document type 2 diabetes, the plan wants you to try a cheaper or preferred drug first, or Rybelsus is not on the drug list. Each has a fix. Send the diagnosis and lab results, show what you already tried, or ask for a formulary exception. If Rybelsus was prescribed for weight loss alone, plans generally will not cover it.

The appeal at a glance
  1. StartThe denial letterFind what was denied, the reason, and the deadline to appeal.
  2. Step 1Appeal to your planMost plans give you 60 to 180 days to ask. The plan reviews its own decision.
  3. Step 2Go outside the planIf it says no again, someone outside the plan can decide: an independent reviewer, a hearing, or a federal office.

Can’t wait? If waiting could seriously harm your health, ask for a fast appeal. Most plans must decide within 72 hours.

What Rybelsus is approved for

Rybelsus is semaglutide in a daily tablet, the same active ingredient as the Ozempic injection. As of November 2026, Rybelsus and Ozempic tablets share one FDA label, which lists two uses for adults with type 2 diabetes:

  • Improving blood sugar control, along with diet and exercise.
  • Lowering the risk of heart attack, stroke and cardiovascular death in adults at high risk for those events.

It is not approved for weight loss.

Why plans deny Rybelsus

No documented diabetes diagnosis. One insurer's employer-plan policy approves Rybelsus with a documented type 2 diabetes diagnosis, and accepts chart notes, lab tests, claims records and prescription receipts as proof. If the request left that out, a resubmission with the diagnosis often fixes it.

Step therapy or a preferred drug. Some plans ask you to try metformin or another GLP-1 first. A 2024 Peterson-KFF review found fewer than 1 in 4 Marketplace plans used step therapy for each GLP-1 studied, but some do. See step therapy denials.

Rybelsus is not on the drug list. Plans publish their drug lists, and a plan may cover one GLP-1 and leave out another. That calls for a formulary exception.

It was prescribed for weight loss. The same policy lists weight loss as not covered, because the diabetes GLP-1s are not FDA-approved for weight loss in people without type 2 diabetes.

Tablet or injection: when the plan prefers another form

Some plans list the injectable GLP-1s and leave the tablet off, or the reverse. One insurer's employer-plan policy lists Rybelsus, Ozempic tablets and Ozempic injection under the same diabetes criteria, but your plan's drug list decides which ones are covered and at what cost.

If your plan prefers an injection, a formulary exception can ask for the tablet. Your doctor's letter should explain why a pill matters for you, such as a documented needle phobia, a hand condition that makes injecting hard, or a bad reaction to an injectable GLP-1, with dates. Job-based plans must cite the specific plan provision behind the denial, so check whether it says "non-formulary" or "step therapy."

What to send with the appeal

Send the appeal in writing and keep copies. Ask your doctor for a letter of medical necessity that includes:

  • The type 2 diabetes diagnosis, with the diagnosis code and date.
  • Recent lab results, such as your A1c, with dates.
  • Every diabetes medicine you have tried, with doses, dates and results or side effects.
  • Any heart disease or other condition that makes Rybelsus the right choice.
  • Why the plan's preferred drug will not work as well for you or would cause harm, if the plan wants a different drug.

Ask the plan for the written criteria it used. Job-based plans must name the specific plan provision behind a denial and give you a free copy of any criteria they relied on. File the internal appeal within 180 days of the denial.

If Rybelsus is not on the drug list, ask for a formulary exception instead of, or alongside, the appeal. Your doctor generally confirms that covered drugs have not worked, will not work as well, or are likely to cause harm. Individual and small-group plans must decide a standard request within 72 hours and an expedited one within 24 hours, and a denial can go to an independent reviewer. See formulary exception letters.

If the plan upholds a denial that turned on medical judgment, you can ask for external review within 4 months of the final decision. Your insurer has to accept the reviewer’s decision.

Medicare and Medicaid

Medicare.gov says Part D plans should cover GLP-1 drugs for type 2 diabetes. With a Medicare drug plan, ask for a coverage determination or exception. Your prescriber must provide a statement explaining the medical reason. The plan must decide within 72 hours, or 24 hours if expedited, and Part D exceptions can also cover step therapy and dose limits. You have 65 days to appeal a denial. See Part D appeals.

State Medicaid programs must cover GLP-1 drugs for diabetes, though they may require prior authorization. See Medicaid appeals.

Novo Nordisk runs NovoCare for support and savings information.

Questions people ask

Why was Rybelsus denied when I have diabetes?

Check whether the request included your type 2 diabetes diagnosis, whether the plan wants metformin or another drug first, and whether Rybelsus is on your plan's drug list.

Will insurance cover Rybelsus for weight loss?

Usually not. Rybelsus is approved for type 2 diabetes, and one insurer's policy lists weight loss as a use it does not cover because the diabetes GLP-1s are not FDA-approved for weight loss without diabetes. Ask your doctor whether a drug approved for weight management fits.

What does a Rybelsus prior authorization need?

At minimum, proof of type 2 diabetes. One policy asks for a documented diagnosis. Plans with step therapy also want records of the drugs you tried first. You can ask for a free copy of your plan's criteria.

Insurance stopped covering Rybelsus after I'd been on it. What can I do?

First find out why: a lapsed prior authorization, a renewal that asked for proof the drug is working, or a drug-list change. Ask your doctor to resubmit with current records. In individual and small-group plans, being in the middle of a course of treatment on a non-formulary drug qualifies for a 24-hour expedited exception. Medicare drug plans must offer a temporary supply in the first 90 days under a new plan, and that process also covers current enrollees affected by formulary changes.

What if my Rybelsus appeal is denied?

If the denial turned on medical judgment, you can ask for external review by an independent reviewer within 4 months of the plan's final decision. A denied formulary exception in an individual or small-group plan can also go to independent review. With Medicare Part D, if the plan upholds its denial you have 60 days to ask a Part D Independent Review Entity to reconsider; see Part D appeals.

Sources

  1. National Library of Medicine (DailyMed): RYBELSUS and OZEMPIC tablets (semaglutide) prescribing information (DailyMed)as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  2. Cigna Healthcare: Drug Coverage Policy IP0701: Diabetes – Glucagon-Like Peptide-1 Agonists for Employer Plans (effective 06/15/2026)Diagnosis of Type 2 diabetes mellitus [Documentation Required]
  3. Peterson-KFF Health System Tracker: Insurer strategies to control costs associated with weight loss drugsstep therapy is much less commonly used as a utilization management tool, with fewer than 1 in 4 Marketplace plans requiring step therapy for each of the drugs included in this analysis
  4. HealthCare.gov: Getting prescription medicationsVisit your insurer’s website to review a list of prescriptions your plan covers
  5. eCFR (Office of the Federal Register): 29 CFR 2560.503-1 -- Claims procedureReference to the specific plan provisions on which the determination is based
  6. HealthCare.gov: Internal appealsYou must file your internal appeal within 180 days (6 months) of receiving notice that your claim was denied.
  7. eCFR (Office of the Federal Register): 45 CFR 156.122 -- Prescription drug benefitsA health plan must make its determination on a standard exception and notify the enrollee or the enrollee's designee and the prescribing physician (or other prescriber, as appropriate) of its coverage determination no later than 72 hours following receipt of the request.
  8. HealthCare.gov: External ReviewYou must file a written request for an external review within 4 months after the date you receive a notice or final determination from your insurer that your claim has been denied.
  9. Medicare.gov: Weight loss drugsYou aren't eligible for the Medicare GLP-1 Bridge, because your Medicare drug plan should cover GLP-1 medications to treat these conditions.
  10. Medicare.gov: Appeals in a Medicare drug planIf you're asking for an exception, your prescriber must provide a statement explaining the medical reason why the exception should be approved.
  11. eCFR (Office of the Federal Register): 42 CFR 423.568 -- Standard timeframe and notice requirements for coverage determinationsbut no later than 72 hours after receipt of the physician's or other prescriber's supporting statement
  12. eCFR (Office of the Federal Register): 42 CFR 423.572 -- Timeframes and notice requirements for expedited coverage determinationsbut no later than 24 hours after receipt of the physician's or other prescriber's supporting statement
  13. eCFR (Office of the Federal Register): 42 CFR 423.578 -- Exceptions processAn exception to a plan's coverage policy that causes a Part D prescription drug not to be covered because of cost utilization tools, such as a requirement for step therapy, dosage limitations, or therapeutic substitution.
  14. KFF: Medicaid Coverage of and Spending on GLP-1sMedicaid coverage of GLP-1 drugs for obesity treatment is optional for states, while coverage for other indications (diabetes, cardiovascular disease, and sleep apnea) is required.
  15. Legal Information Institute, Cornell Law School: 42 U.S. Code § 1396r-8 - Payment for covered outpatient drugsA State may subject to prior authorization any covered outpatient drug
  16. Novo Nordisk: Support Starts Here for Patients Taking Novo Medicines | Novocare®offers the guidance, savings, and support you need to keep moving forward
  17. eCFR (Office of the Federal Register): 42 CFR 423.120 -- Access to covered Part D drugsEnsure access to a temporary supply of drugs within the first 90 days of coverage under a new plan.

This page is general information about appeal rules in the United States. It is not legal or medical advice. Rules can change, and your plan’s documents and your denial letter control the dates that apply to you.